TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
APGE

Apogee Therapeutics, Inc.

Healthcare · Biotechnology

135.10$ +0.0% vs. previous close Closing price · As of: Sep 3, 2026

Investor relations

Report Dates

Investor relations overview for Apogee Therapeutics, Inc. (APGE): report dates, earnings surprises, earnings call transcripts and the latest headlines. The next report is scheduled for 08/10/2026.

Next report 08/10/2026
Last report 08/10/2026
Earnings surprise by quarter (%)
Q3 23 · -21.4 % 23 Q4 23 · 34.7 % 23 Q1 24 · 1.5 % 24 Q2 24 · -9.1 % 24 Q3 24 · -16.2 % 24 Q4 24 · -90.3 % 24 Q1 25 · 20.2 % 25 Q2 25 · -7.6 % 25 Q3 25 · 3.5 % 25 Q4 25 · -66.1 % 25 Q1 26 · 6.2 % 26 Q2 26 · -3.6 % 26

EPS estimate beaten

Full history 5 of 14 quarters (36%)

Earnings Call Transcripts

Search all transcripts →

No transcripts yet — they will show up here automatically after the next earnings call.

News on This Stock

  • 09/03/2026 Apogee Therapeutics, Inc. (APGE): Termination of a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Material Modifications to Rights of Security Holders; Changes in Control of Registrant; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Amendments to Articles of Inco · sec.gov Open ↗
  • 08/11/2026 Apogee Therapeutics, Inc. (APGE): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Submission of Matters to a Vote of Security Holders · sec.gov Open ↗
  • 08/10/2026 Apogee Therapeutics, Inc. (APGE): Results of Operations and Financial Condition; Financial Statements and Exhibits · sec.gov Open ↗

Automatically matched wire and portal stories; external links open the original source.

Data as of: September 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Transcripts: transcript archive

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?